Mirum Pharmaceuticals (MIRM)
NASDAQ:MIRM
Want to see MIRM full AI Analyst Report?
MIRM Stock Chart & Stats
$97.95
-$0.27(-0.64%)
At close: 4:00 PM EST
$97.95
-$0.27(-0.64%)
Day’s Range― - ―
52-Week Range$47.89 - $114.99
Previous CloseN/A
Volume92.82K
Average Volume (3M)1.08M
Market Cap
$6.53B
Enterprise Value$5.12B
Total Cash (Recent Filing)$386.26M
Total Debt (Recent Filing)$323.78M
Price to Earnings (P/E)―
Beta0.83
Next Earnings
Jul 30, 2026EPS Estimate
-0.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-13.61
Shares Outstanding60,981,228
10 Day Avg. Volume783,111
30 Day Avg. Volume1,081,550
Financial Highlights & Ratios
PEG Ratio2.28
Price to Book (P/B)12.60
Price to Sales (P/S)7.61
P/FCF Ratio72.26
Enterprise Value/Market Cap0.78
Enterprise Value/Revenue8.99
Enterprise Value/Gross Profit11.05
Enterprise Value/Ebitda-6.73
Forecast
1Y Price Target
$145.36Price Target Upside48.40% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-15.65
Revenue Forecast (FY)$674.49M
Bulls Say, Bears Say
Bulls Say
Sustained Product Revenue Growth And Raised GuidanceConsistent, high-single-digit to double-digit organic sales growth and an upward revision to full-year guidance reflect durable commercial traction for LIVMARLI and related products. This indicates expanding adoption and pricing power in rare hepatology niches, supporting multi‑period revenue visibility while management scales commercialization.
Strong Product-level EconomicsVery high gross margins and a mid‑50% cash contribution margin point to favorable unit economics for marketed therapies. These durable margins create room to absorb increased R&D and SG&A as the company scales, supporting the path to operating leverage and eventual sustained cash generation once fixed investments moderate.
De‑risked Pipeline With Near-term Regulatory CatalystsMultiple successful late‑stage signals across PSC, HDV and FOP plus an accepted NDA with a defined PDUFA create structural optionality beyond the core product. These regulatory milestones and late‑stage data materially increase the chance of new product launches and revenue diversification over the next 12–24 months.
Bears Say
Renewed TTM Operating Cash BurnThe recent return to significant TTM cash outflow and minimal near‑term operating cash generation limits runway and increases reliance on financing. Over the coming months this structural cash volatility could constrain optionality, force prioritization of programs, or require further capital raises until launches drive steady cash flow.
Elevated Leverage And Larger Debt FootprintA materially higher debt burden versus earlier years reduces financial flexibility and raises refinancing and covenant risk if operating losses persist. With profitability pushed into the future, elevated leverage heightens the company's sensitivity to cash‑flow shortfalls and increases the cost of optional strategic moves.
Limited Addressable FOP Market And Data UncertaintiesUltra‑rare indication sizes and diagnostic challenges cap peak revenue potential and complicate launch execution, while subgroup variability in trials creates uncertainty about replicability and regulatory robustness. Together, small patient pools and data questions sustain structural commercial and approval risk for certain pipeline assets.
Mirum Pharmaceuticals News
MIRM FAQ
What was Mirum Pharmaceuticals’s price range in the past 12 months?
Mirum Pharmaceuticals lowest stock price was $47.89 and its highest was $114.99 in the past 12 months.
What is Mirum Pharmaceuticals’s market cap?
Mirum Pharmaceuticals’s market cap is $6.53B.
When is Mirum Pharmaceuticals’s upcoming earnings report date?
Mirum Pharmaceuticals’s upcoming earnings report date is Jul 30, 2026 which is in 40 days.
How were Mirum Pharmaceuticals’s earnings last quarter?
Mirum Pharmaceuticals released its earnings results on May 06, 2026. The company reported -$13.43 earnings per share for the quarter, missing the consensus estimate of -$0.365 by -$13.065.
Is Mirum Pharmaceuticals overvalued?
According to Wall Street analysts Mirum Pharmaceuticals’s price is currently Undervalued.
Does Mirum Pharmaceuticals pay dividends?
Mirum Pharmaceuticals does not currently pay dividends.
What is Mirum Pharmaceuticals’s EPS estimate?
Mirum Pharmaceuticals’s EPS estimate is -0.74.
How many shares outstanding does Mirum Pharmaceuticals have?
Mirum Pharmaceuticals has 60,981,228 shares outstanding.
What happened to Mirum Pharmaceuticals’s price movement after its last earnings report?
Mirum Pharmaceuticals reported an EPS of -$13.43 in its last earnings report, missing expectations of -$0.365. Following the earnings report the stock price went down -6.495%.
Which hedge fund is a major shareholder of Mirum Pharmaceuticals?
Currently, no hedge funds are holding shares in MIRM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mirum Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$145.36 (48.40% Upside)
$145.36 (48.40% Upside)
Blogger Sentiment
Bullish
MIRM Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 576.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.6%
Last 30 Days ▲ 7.6%
Last 30 Days ▲ 7.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
110.88%
12-Months-Change
Fundamentals
Return on Equity
-289.33%
Trailing 12-Months
Asset Growth
29.07%
Trailing 12-Months
Company Description
Mirum Pharmaceuticals
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
MIRM Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented strong commercial momentum and meaningful pipeline and BD progress: solid Q1 sales growth (~42.9% YoY), an upward revision to full-year guidance, funded R&D investments, prioritized near-term regulatory catalysts (including a PDUFA on September 26, 2026), and a plan to scale the commercial team. These positives are tempered by a very large, one-time operating expense tied to the Bluejay acquisition that drove an unusually high quarterly operating charge ($761M of $949M), minimal Q1 operating cash flow (~$2M), elevated R&D spend, and remaining data and market-size uncertainties for some pipeline assets (e.g., FOP patient counts and certain subgroup signals in hepatitis delta). Management expects operating cash flow positivity next year and GAAP profitability by 2028, indicating confidence in the business model despite near-term accounting and investment-driven headwinds.View all MIRM earnings summariesMIRM Stock 12 Month Forecast
Average Price Target
$145.36
▲(48.40% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
Catalyst Pharma
―
Ultragenyx Pharmaceutical
―
ImmunityBio
―
―
Ownership Overview
7.99% Insiders
29.27% Mutual Funds
48.40% Other Institutional Investors
1.18% Public Companies and
Individual Investors